Antidepressive treatments for Parkinson's disease: A systematic review and meta-analysis

Bomasang-Layno, Emily; Fadlon, Iris; Murray, Andrea N.; Himelhoch, Seth

doi:10.1016/j.parkreldis.2015.04.018

Cited by 125 publications

(83 citation statements)

References 67 publications

(97 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Besides, different studies could draw contradictive conclusions. For example, Bomasang-Layno et al [60] concluded from 13 trials that SSRI could significantly improve depression of PD with high efficacy, which is consistence with our results. Yet Troeung et al [61] observed in their study that the pooled effects of antidepressive medication in PD were insignificant, which involved 9 clinical trials.…”

Section: Discussionsupporting

confidence: 92%

Efficacy of antidepressive medication for depression in Parkinson disease

et al. 2017

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 92%

Efficacy of antidepressive medication for depression in Parkinson disease

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Thus, the mechanism of ECT in treating PD-related depression may be a result of increased dopamine receptor binding caused by electroconvulsive stimulation in brain regions implicated in depression such as the nucleus accumbens (24,25). It is likely that the anti-depressant mechanism of ECT is not completely unique in PD patients (26). …”

Section: Discussionmentioning

confidence: 99%

Unilateral ultra-brief pulse electroconvulsive therapy for depression in Parkinson's disease

et al. 2016

View full text Add to dashboard Cite

Objectives Electroconvulsive therapy (ECT) has demonstrated efficacy in treating core symptoms of Parkinson’s disease (PD), however widespread use of ECT in PD has been limited due to concern over cognitive burden. We investigated the use of a newer ECT technology known to have fewer cognitive side effects (right unilateral (RUL) ultrabrief pulse (UBP)) for the treatment of medically-refractory psychiatric dysfunction in PD. Materials and methods This open label pilot study included 6 patients who were assessed in the motoric, cognitive and neuropsychiatric domains prior to and after RUL UBP ECT. Primary endpoints were changes in total score on the HAM-D-17 and GDS-30 rating scales. Results Patients were found to improve in motoric and psychiatric domains following RUL UBP ECT without cognitive side effects, both immediately following ECT and at 1-month follow-up. Conclusions This study demonstrates that RUL UBP ECT is safe, feasible and potentially efficacious in treating multiple domains of PD, including motor and mood, without clear cognitive side effects.

show abstract

“…This includes depression in PD (Bomasang-layno et al, 2015; Jaunarajs et al, 2011; Lewitt, 2012; Troeung et al, 2013). Degeneration of the locus coeruleus, the source of noradrenergic projection neurons in the brain, occurs in PD relatively early in Braak Stage 2 (Table 1) (Goedert et al, 2013).…”

Section: Parkinson’s Diseasementioning

confidence: 99%

Neuroimaging of Parkinson's disease: Expanding views

Weingarten

Sundman

Hickey

et al. 2015

Neuroscience & Biobehavioral Reviews

137

View full text Add to dashboard Cite

Advances in molecular and structural and functional neuroimaging are rapidly expanding the complexity of neurobiological understanding of Parkinson’s disease (PD). This review article begins with an introduction to PD neurobiology as a foundation for interpreting neuroimaging findings that may further lead to more integrated and comprehensive understanding of PD. Diverse areas of PD neuroimaging are then reviewed and summarized, including positron emission tomography, single photon emission computed tomography, magnetic resonance spectroscopy and imaging, transcranial sonography, magnetoencephalography, and multimodal imaging, with focus on human studies published over the last five years. These included studies on differential diagnosis, co-morbidity, genetic and prodromal PD, and treatments from L-DOPA to brain stimulation approaches, transplantation and gene therapies. Overall, neuroimaging has shown that PD is a neurodegenerative disorder involving many neurotransmitters, brain regions, structural and functional connections, and neurocognitive systems. A broad neurobiological understanding of PD will be essential for translational efforts to develop better treatments and preventive strategies. Many questions remain and we conclude with some suggestions for future directions of neuroimaging of PD.

show abstract

Antidepressive treatments for Parkinson's disease: A systematic review and meta-analysis

Abstract: This meta-analysis demonstrates that pharmacologic treatment with antidepressant medications, specifically the selective serotonin reuptake inhibitors (SSRIs), and behavioral interventions (CBT) significantly improved depression among Parkinson's disease patients.

Cited by 125 publications

References 67 publications

Efficacy of antidepressive medication for depression in Parkinson disease

Efficacy of antidepressive medication for depression in Parkinson disease

Unilateral ultra-brief pulse electroconvulsive therapy for depression in Parkinson's disease

Neuroimaging of Parkinson's disease: Expanding views

Contact Info

Product

Resources

About